ClinicalTrials.gov
public full text
Public Domain
Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects
This study is not being conducted in the United States. To investigate the relative efficacy of pimecrolimus cream 1% applied twice daily (b.i.d.) versus once daily (o.d.) in preventing the progression to disease "relapse".
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Dupilumab De-escalation in Pediatric Atopic Dermatitis#835866
- Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis#903746
- Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis#1007571
- Severity bands for atopic dermatitis measures: analysis from adult dupilumab randomized clinical trials / Andreas Wollenberg, Eric L. Simpson, Yael A. Leshem, Alain Taïeb, Norito Katoh, Jingdong Chao, Ana B. Rossi, Amy H. Praestgaard#783932
- Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)#982638
Record · ID 1152484
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive